丹红注射液加生脉注射液治疗进展性缺血性脑卒中NIHSS量表观察  

Observation of NIHSS in Patients with Progressive Ischemic Stroke Treatment with Dan-Hong Injection and Sheng-Mai Injection

作　　者：丁文涛[1] 

机构地区：[1]中国中医科学院广安门医院南区针灸脑病科,北京102618

出　　处：《成都中医药大学学报》2014年第4期60-62,共3页Journal of Chengdu University of Traditional Chinese Medicine

摘　　要：目的:通过观察丹红注射液加生脉注射液治疗进展性缺血性脑卒中的NIHSS量表变化,评价其临床疗效。方法:将120例进展性缺血性脑卒中患者随机分为观察组与对照组各60例。在常规治疗的基础上,观察组加用丹红注射液加生脉注射液治疗,对照组加用羟乙基淀粉酶静脉注射治疗。2组均治疗14w后根据NIHSS量表评分进行疗效评价。结果:两组治疗后NIHSS评分均有不同程度降低;与羟乙基淀粉组对照,应用丹红注射液加生脉注射液治疗进展性缺血性脑卒中NIHSS评分改善更明显,两组对比有显著性意义(P<0.05)。结论:丹红注射液加生脉注射液配合常规治疗,治疗进展性缺血性脑卒中具有明显疗效优势。Objective： To observe the changes of the NIHSS on patients with progressive ischemic stroke after treatment with Dan-hong injection plus Sheng-mai Injection and evaluate their clinical efficacy. Methods： 120 patients with progressive stroke were randomly divided into observation group and control group with 30 cases in each. On the basis of routine treatment, the observation group treated with Danhong injection plus Sheng-mai injection, the control group were treated with intravenous injection of hydroxyethyl starch. Clinical efficacy was evaluated by the change of NIHSS after treating for 14 days. Results： The NIHSSs were decreased in dif- ferent degree after treatment in both groups. Compared with control group, the improvement of NIHSS in observation group was signifi- cant （P 〈 0. 05） . Conclusion： Dan-hong injection and Sheng-mai injection in treatment of progressive ischemic stroke has the obvi- ous efficacy.

关 键 词：进展性卒中 缺血性卒中 丹红注射液 生脉注射液 NIHSS 

分 类 号：R283.61[医药卫生—中药学] R255.2[医药卫生—中医学]